Sarepta Therapeutics, Inc. $SRPT Shares Acquired by Federated Hermes Inc.

Federated Hermes Inc. boosted its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 347.8% in the second quarter, Holdings Channel reports. The fund owned 1,308,199 shares of the biotechnology company’s stock after purchasing an additional 1,016,069 shares during the period. Federated Hermes Inc.’s holdings in Sarepta Therapeutics were worth $22,370,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in SRPT. Norges Bank acquired a new position in shares of Sarepta Therapeutics during the 2nd quarter worth $15,619,000. Y Intercept Hong Kong Ltd grew its holdings in Sarepta Therapeutics by 1,736.5% during the 2nd quarter. Y Intercept Hong Kong Ltd now owns 870,181 shares of the biotechnology company’s stock valued at $14,880,000 after buying an additional 822,799 shares during the last quarter. Aberdeen Group plc boosted its stake in shares of Sarepta Therapeutics by 91.1% during the second quarter. Aberdeen Group plc now owns 1,242,404 shares of the biotechnology company’s stock valued at $21,500,000 after acquiring an additional 592,125 shares during the last quarter. Wellington Management Group LLP grew its holdings in shares of Sarepta Therapeutics by 27.9% during the first quarter. Wellington Management Group LLP now owns 2,646,619 shares of the biotechnology company’s stock worth $168,907,000 after buying an additional 577,848 shares in the last quarter. Finally, EcoR1 Capital LLC raised its holdings in Sarepta Therapeutics by 67.8% in the 1st quarter. EcoR1 Capital LLC now owns 1,292,386 shares of the biotechnology company’s stock valued at $82,480,000 after acquiring an additional 522,386 shares during the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have issued reports on SRPT shares. Leerink Partners raised their price target on Sarepta Therapeutics from $12.00 to $15.00 and gave the stock a “market perform” rating in a research note on Tuesday, September 9th. Mizuho raised shares of Sarepta Therapeutics from a “neutral” rating to an “outperform” rating and raised their target price for the stock from $19.00 to $26.00 in a research report on Wednesday, November 5th. Barclays lowered their target price on shares of Sarepta Therapeutics from $22.00 to $20.00 and set an “equal weight” rating for the company in a report on Wednesday, November 5th. Wedbush started coverage on shares of Sarepta Therapeutics in a research note on Tuesday. They set an “outperform” rating and a $32.00 price target on the stock. Finally, HC Wainwright reissued a “sell” rating on shares of Sarepta Therapeutics in a research note on Monday, August 25th. Nine analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and six have given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $33.68.

Sarepta Therapeutics Stock Performance

Shares of SRPT stock opened at $22.17 on Wednesday. The company has a current ratio of 2.95, a quick ratio of 1.79 and a debt-to-equity ratio of 0.78. The company has a market cap of $2.32 billion, a PE ratio of -7.37 and a beta of 0.54. The company’s fifty day simple moving average is $20.91 and its 200-day simple moving average is $21.21. Sarepta Therapeutics, Inc. has a 52 week low of $10.41 and a 52 week high of $129.84.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Monday, November 3rd. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.15). The company had revenue of $399.36 million during the quarter, compared to analyst estimates of $331.51 million. Sarepta Therapeutics had a negative net margin of 11.25% and a negative return on equity of 4.85%. The firm’s revenue for the quarter was down 14.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.62 earnings per share. As a group, equities research analysts anticipate that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.